Treace Medical Concepts Q2 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $44.455M Beat $43.000M Estimate
Treace Medical Concepts Q2 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $44.455M Beat $43.000M Estimate
Treace醫療概念2024年第二季度GAAP EPS爲$(0.34)，低於$(0.29)的預估值，銷售額爲4445.5萬美元，高於4300萬美元的預估值。
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 70 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $44.455 million which beat the analyst consensus estimate of $43.000 million by 3.38 percent. This is a 5.96 percent increase over sales of $41.953 million the same period last year.
Treace Medical Concepts (納斯達克股票代碼：TMCI)報告本季度每股虧損0.34美元，未達到分析師平均預期的0.29美元，下降17.24％。這是相對於去年同期每股虧損0.20美元的70％下降。該公司本季度銷售額爲4445.5萬美元，超過分析師平均預期的4300萬美元，增長3.38％。這是相對於去年同期銷售額4195.3萬美元的增長5.96％。